Effect of Thalidomide on Cox-2 expression in bleomycin-induced pulmonary fibrosis in mice
Open Access
- 4 January 2019
- journal article
- research article
- Published by Biomedical Research and Therapy in Biomedical Research and Therapy
- Vol. 6 (1), 2974-2982
- https://doi.org/10.15419/bmrat.v6i1.518
Abstract
Introduction: Lung fibrosis is a progressive, fatal disease that is characterized by increasing fibroblasts proliferation and extracellular matrix precipitation. Studies have shown that cyclooxygenase- 2 (Cox-2) could play a crucial role in the pathogenesis of lung fibrosis. In the current study, the effect of thalidomide on bleomycin-induced pulmonary fibrosis was qualitatively studied in a laboratory animal model. Methods: Thirty-two adult male C57BL/6 mice were randomly assigned to the following four groups: Group one received 2 mg bleomycin, group two received bleomycin in addition to 4 mg of thalidomide; group three received 4 mg of thalidomide, and Group 4 received 0.1 mg of 0.5% carboxymethyl cellulose (CMC) via intraperitoneal (IP) administration. Finally, the expression of Cox-2 protein and the percentage of contact points of alveolar spaces and pulmonary connective tissue were determined. Results: Our results showed that in the Bleo + Thal group compared to the Bleo group, the percentage of contact points of pulmonary connective tissue decreased significantly (P<0.001), while the percentage of contact points among the alveolar spaces increased significantly (P = 0.01). Also, immunohistochemical studies have demonstrated the number of Cox-2+ cells in the volume unit in the Bleo + Thal group decreased significantly in comparison with the group that received only Bleo (P = 0.012). Conclusion: In conclusion, these results suggest thalidomide could alleviate the bleomycin-induced lung fibrosis and decreases the expression of Cox-2 protein.Keywords
This publication has 8 references indexed in Scilit:
- Silymarin alleviates bleomycin-induced pulmonary toxicity and lipid peroxidation in micePharmaceutical Biology, 2014
- Diagnosis and management of interstitial lung diseaseTranslational Respiratory Medicine, 2014
- Thalidomide for the Treatment of Cough in Idiopathic Pulmonary FibrosisAnnals of Internal Medicine, 2012
- Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studiesClinical and Experimental Immunology, 2009
- Cyclooxygenase-2 expression in experimental post-transplant obliterative bronchiolitisThe Journal of Pathology, 2004
- A Study of the Cough Reflex in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomideAmerican Journal of Hematology, 2003
- The treatment of advanced renal cell cancer with high-dose oral thalidomideBritish Journal of Cancer, 2001